Bioquímica y Biología Molecular
Departamento
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (12)
2023
-
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
Cell, Vol. 186, Núm. 12, pp. 2628-2643.e21
2022
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2019
-
Genome mining and characterisation of a novel transaminase with remote stereoselectivity
Scientific Reports, Vol. 9, Núm. 1
2018
-
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer
Cell Death and Differentiation, Vol. 25, Núm. 5, pp. 828-840
2016
2012
-
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy, Vol. 8, Núm. 4, pp. 445-544
2006
-
Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization
Journal of Cardiovascular Pharmacology, Vol. 47, Núm. 1, pp. 60-69
2005
-
HMG-CoA reductase inhibitors reduce IκB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells
Journal of Cardiovascular Pharmacology, Vol. 45, Núm. 5, pp. 468-475
-
Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month
Stroke, Vol. 36, Núm. 8, pp. 1796-1800
2002
-
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells
Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58